ICM-203

GENETIC3 trials

Sponsors

ICM Biotech Australia Pty Ltd., ICM Co. Ltd.

Conditions

Osteoarthritis, Knee

Phase 1

A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

CompletedNCT04875754

ICM Biotech Australia Pty Ltd.Osteoarthritis, Knee

Start: 2022-03-17End: 2026-02-20Updated: 2026-09-03

A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.

WithdrawnNCT05454566

ICM Co. Ltd.Osteoarthritis, Knee

Start: 2026-11-15End: 2028-11-15Updated: 2026-09-08

Unknown Phase

A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo

Active, not recruitingNCT05752032

ICM Co. Ltd.Osteoarthritis, Knee

Start: 2023-03-16End: 2029-07-01Updated: 2026-09-03